Details of the Drug Reposition

General Information of This Drug (ID: DMXRJ1N)

Drug Name
PRAME antigen-specific cancer immunotherapeutic   DMXRJ1N

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 1 [2]
Metastatic melanoma DISSL43L 2E2Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01853878) A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of GlaxoSmithKline.